COYA Coya Therapeutics
- 8.250
- -0.350-4.07%
Coya Therapeutics News
Express News | Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Serum 4-HNE levels are increased in bulbar vs. limb onset ALS patients and correlate with shortened survival in patients with bulbar onset ALS;
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024. The title of the poster is 4-hydroxynonenal (4-HNE) as a Biomarker in ALS.
We're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Rate
Coya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate Updates
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Coya Therapeutics, Inc. (COYA) and Iovance Biotherapeutics (IOVA)
Coya Therapeutics Is Maintained at Buy by Chardan Capital
Coya Therapeutics Is Maintained at Buy by Chardan Capital
Express News | Chardan Capital Maintains Buy on Coya Therapeutics, Raises Price Target to $14
Coya Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 31.09% Chardan Capital $11 → $14 Maintains Buy 08/09/2023 162.17% EF Hutton → $28 Reiterates Bu
Strengthened Financials and Promising Pipeline Position Coya Therapeutics for Success
Coya Therapeutics GAAP EPS of -$0.79
Coya Therapeutics Financial Update and Performance Review
Coya Therapeutics FY23 EPS $(0.79) Vs $(4.73) YoY; Collaboration Revenue Of 6M
Financial ResultsAs of December 31, 2023, Coya had cash and cash equivalents of $32.6 million and received an additional $7.5 million in January from Dr. Reddy's as an upfront payment as part of the C
Press Release: Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results HOUSTON--(BUSINESS WIRE)--March 19, 2024-- Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
Buy Recommendation for Coya Therapeutics on Promising Neurodegenerative Disease Treatment Approach
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
Regulatory T cell (Treg) immunomodulatory function significantly compromised and inflammatory cytokines and chemokines significantly increased in FTD patients COYA 302, Coya's lead investigational product, is believed
Coya Therapeutics(COYA.US) Director Buys US$3,620 in Common Stocks
$Coya Therapeutics(COYA.US)$ Director Lee Ann purchased 1,000 shares of Common Stocks on Aug 22, 2023 at an average price of $3.62 for a total value of $3,620.Source: Announcement What is statement of
Analysis
Price Target
No Data
